Assurant
AIZ
$237.14
+3.50%
Assurant, Inc. is a global protection company specializing in insurance and service contracts for connected devices, homes, and automobiles, operating within the specialty insurance industry. The company is a distinct partner to major brands, acting as a critical service provider that enables them to offer protection plans, which positions it as a key niche player in the ecosystem rather than a direct consumer-facing insurer. The current investor narrative is likely focused on the company's ability to navigate economic cycles impacting its Global Housing segment, such as lender-placed insurance, while capitalizing on the resilient demand in its Global Lifestyle segment, which includes mobile device protection, a market driven by ongoing consumer electronics adoption and replacement cycles.…
AIZ
Assurant
$237.14
Investment Opinion: Should I buy AIZ Today?
Rating & Thesis: AIZ is rated a Hold with a Cautious Value thesis. The core reasoning is that the stock appears fundamentally undervalued on forward earnings, but this value is contingent on a significant earnings recovery that lacks strong analyst validation and is occurring amidst persistent market underperformance.
Supporting Evidence: The Hold rating is supported by four key data points: 1) A compelling forward P/E of 10.47x, 2) A PEG ratio of 0.74 suggesting undervaluation relative to growth, 3) Strong underlying profitability with a 77.15% gross margin and 14.86% ROE, and 4) A conservative balance sheet with a 0.38 debt-to-equity ratio. However, these are offset by a -6.92% 3-month relative strength versus the SPY and reliance on a single analyst's EPS estimate.
Risks & Conditions: The two biggest risks are the failure of EPS to recover to the $22.92 estimate and continued relative underperformance. This Hold would upgrade to a Buy if the stock demonstrates sustained earnings momentum in upcoming reports, causing the forward P/E to compress further, or if it breaks above the $246 resistance on strong volume. It would downgrade to a Sell if quarterly EPS meaningfully misses the $22.92 trajectory or if the price breaks below the $183 support level. The valuation verdict is that AIZ is fairly valued to slightly undervalued based on forward estimates, but fully valued given current earnings and market sentiment.
Sign up to view all
AIZ 12-Month Price Forecast
The outlook for AIZ is neutral with medium confidence. The stock presents a classic value trap scenario: attractive forward multiples are entirely dependent on an earnings rebound that lacks broad analyst confirmation. The low beta and strong margins offer downside protection, but the catalyst for a re-rating is unclear given its history of underperformance. The stance would upgrade to bullish on concrete evidence of the EPS recovery (e.g., two consecutive quarters meeting the run-rate) and a breakout above $246. It would turn bearish on a breakdown below $210 with deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Assurant's 12-month outlook, with a consensus price target around $308.28 and implied upside of +30.0% versus the current price.
Average Target
$308.28
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$190 - $308
Analyst target range
Analyst coverage for Assurant appears limited, with data indicating only one analyst providing estimates, which suggests insufficient coverage to derive a meaningful consensus recommendation or price target. This limited coverage typically implies the stock is a mid-cap company ($12.2B market cap) with lower institutional interest, which can lead to higher volatility and less efficient price discovery as it falls outside the purview of many large sell-side firms. The single analyst's revenue estimate for the coming year averages $14.75 billion, with a range from $14.37B to $15.36B, indicating moderate growth expectations and relatively low uncertainty around the top-line forecast. The estimated EPS range is wider on a percentage basis, from $22.15 to $24.14, with an average of $22.92; the high-end target likely assumes better-than-expected margin expansion or lower claims, while the low-end may factor in competitive pressures or higher loss ratios.
Bulls vs Bears: AIZ Investment Factors
The evidence currently tilts slightly bullish, primarily due to AIZ's compelling valuation metrics (forward P/E of 10.5x, PEG of 0.74) and strong underlying profitability (77% gross margin) paired with a conservative balance sheet. However, the bear case is supported by the stock's persistent market underperformance and the significant leap of faith required in its earnings recovery narrative. The single most important tension in the investment debate is whether the forecasted EPS normalization to ~$22.92 materializes as expected. If it does, the stock is deeply undervalued; if not, the low trailing earnings and limited analyst scrutiny could lead to further de-rating.
Bullish
- Undervalued Forward P/E of 10.5x: The stock trades at a forward P/E of 10.47x based on estimated EPS of $22.92, which is a significant discount to the broader market and suggests a low valuation for a profitable financial services firm. This is further supported by a PEG ratio of 0.74, indicating the stock is cheap relative to its expected earnings growth.
- Strong Profitability and Pricing Power: Assurant exhibits robust underlying profitability with a gross margin of 77.15% and a net margin of 6.81%, demonstrating effective cost management and pricing power in its niche insurance segments. A healthy Return on Equity of 14.86% confirms efficient use of shareholder capital.
- Conservative Balance Sheet with Low Leverage: The company maintains a strong financial position with a low debt-to-equity ratio of 0.38, indicating minimal financial risk and ample capacity to weather economic downturns. This conservative structure is a key defensive attribute for an insurance business.
- Low Beta Provides Defensive Characteristics: With a beta of 0.56, AIZ has historically been 44% less volatile than the S&P 500, making it a potential portfolio stabilizer during market turbulence. This low correlation is evidenced by its 20.8% 1-year gain despite underperforming the SPY by 8.2 percentage points.
Bearish
- Limited Analyst Coverage and Visibility: Only one analyst provides estimates for AIZ, resulting in low institutional interest and potentially inefficient price discovery for this $12.2B market cap company. This limited coverage increases the risk of earnings surprises and can lead to higher volatility, as seen in the sharp single-day drops in the price history.
- Weak Relative Strength vs. Market: AIZ has underperformed the SPY over the past 1-year, 3-month, and year-to-date periods, with a -8.23%, -6.92%, and -8.29% relative strength, respectively. This persistent underperformance suggests the market is assigning a lower growth premium to the stock despite its low valuation.
- Anomalously Low Trailing EPS Raises Questions: The trailing twelve-month EPS of $0.07 is extremely low relative to the stock price, creating a high trailing P/E of 13.93x. While the forward P/E is attractive, the disparity highlights recent earnings pressure and places full reliance on a significant forecasted earnings recovery to $22.92.
- Low Current Ratio for an Insurance Firm: A current ratio of 0.55 is low, though typical for insurance companies where liabilities are long-term. It nonetheless indicates limited short-term liquidity flexibility, which could be a concern if unexpected claims or operational needs arise rapidly.
AIZ Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a 20.81% 1-year price increase, but is currently consolidating after a significant pullback from its highs. With a current price of $231.51, it is trading at approximately 73% of its 52-week range ($183.39 to $246.31), indicating it has retreated meaningfully from its peak and is now in a middle-ground position that could represent either a consolidation before another leg up or a potential distribution phase. Recent short-term momentum shows a sharp divergence, with a strong 7.02% gain over the past month contrasting with a -2.78% loss over the past three months, suggesting the stock experienced a volatile correction in February/March and is now attempting a recovery rally. This 1-month surge, which occurred against a -6.92% relative strength versus the SPY over 3 months, signals a potential mean reversion or short-term rebound within a longer-term choppy trend. Key technical support is clearly defined at the 52-week low of $183.39, while immediate resistance sits at the 52-week high of $246.31; a decisive breakout above $246 would signal a resumption of the primary bull trend, whereas a breakdown below $183 would indicate a major trend reversal. The stock's beta of 0.56 indicates it is 44% less volatile than the broader market (SPY), which is significant for risk management as it suggests the stock has acted as a relative safe haven during recent market turbulence, though its sharp single-day drops (e.g., from $243 to $216 in early February) reveal it is not immune to stock-specific event risk.
Beta
0.56
0.56x market volatility
Max Drawdown
-15.1%
Largest decline past year
52-Week Range
$183-$246
Price range past year
Annual Return
+20.7%
Cumulative gain past year
| Period | AIZ Return | S&P 500 |
|---|---|---|
| 1m | +8.7% | +10.4% |
| 3m | -1.7% | +5.5% |
| 6m | +9.4% | +8.0% |
| 1y | +20.7% | +28.4% |
| ytd | -0.2% | +6.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AIZ Fundamental Analysis
Revenue trajectory analysis is constrained as specific quarterly revenue and growth rate figures are not available in the provided dataset; however, analyst estimates point to expected annual revenue of approximately $14.75 billion, suggesting the market anticipates a stable top-line. The company's profitability is solid, with a net margin of 6.81% and a robust gross margin of 77.15%, indicating strong underlying pricing power and cost management in its insurance and service operations. The trailing twelve-month EPS of $0.07 appears anomalously low relative to the stock price, but the forward P/E of 10.47 based on estimated EPS of $22.92 implies the market expects a significant normalization and return to substantial profitability in the coming year. Balance sheet health appears strong, with a conservative debt-to-equity ratio of 0.38, suggesting limited financial leverage risk, and a current ratio of 0.55, which is low for a non-financial firm but typical for insurance companies where liabilities are matched with long-term assets. The return on equity of 14.86% is healthy and indicates efficient use of shareholder capital, while the payout ratio of 19.3% and dividend yield of 1.39% demonstrate a commitment to returning capital while retaining ample earnings for reinvestment and growth.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AIZ Overvalued?
The primary valuation metric selected is the Price-to-Earnings (P/E) ratio, as the company is profitable with a positive net margin. The trailing P/E of 13.93x is based on depressed recent earnings, while the forward P/E of 10.47x is derived from significantly higher estimated EPS, indicating the market expects a substantial earnings recovery and is currently valuing the stock on that forward outlook. Compared to sector averages, the stock trades at a discount based on its sales multiple, with a Price-to-Sales ratio of 0.95x and an EV/Sales of 0.92x; these multiples are typically low for financial services firms, suggesting the market assigns a lower growth premium or reflects the capital-intensive nature of the insurance business. The PEG ratio of 0.74, based on forward earnings, suggests the stock is undervalued relative to its expected growth rate, a point reinforced by the EV/EBITDA of 8.66x, which is reasonable for a stable financial services company. Historical context for valuation is limited without specific historical ratio data, but the current P/B ratio of 2.07x provides a baseline; given the stock's price is below its 52-week high, it is likely not at peak historical valuation multiples, potentially offering a value opportunity if the earnings recovery materializes as forecasted.
PE
13.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the reliance on a forecasted earnings recovery, as current trailing EPS of $0.07 is depressed. While the balance sheet is strong with a 0.38 debt-to-equity ratio, the low current ratio of 0.55, though industry-typical, limits short-term liquidity. Operational risk is concentrated in the cyclicality of the Global Housing segment, which could see margin compression during an economic slowdown, potentially jeopardizing the path to the estimated $22.92 EPS.
Market & Competitive Risks: The key market risk is valuation compression; despite trading at a discount on a forward basis, the stock's persistent underperformance versus the SPY (e.g., -8.23% over 1 year) suggests it is out of favor. Its low beta of 0.56, while defensive, also means it may not participate fully in market rallies. Competitive risks include potential disruption in its niche protection markets or pressure from larger insurers, though its partner-based model provides some insulation.
Worst-Case Scenario: The worst-case scenario involves the forecasted earnings recovery failing to materialize due to a severe housing downturn impacting the Global Housing segment and/or a loss of key brand partners in the Lifestyle segment. This could trigger analyst downgrades (though coverage is sparse) and a re-rating to a higher discount. A realistic downside could see the stock retesting its 52-week low of $183.39, representing a potential loss of approximately -21% from the current price of $231.51.
FAQ
The key risks are, in order of severity: 1) Execution/Earnings Risk: The stock's valuation hinges on EPS recovering to $22.92; missing this target is the primary risk. 2) Market Sentiment Risk: Persistent relative underperformance versus the SPY (e.g., -6.92% over 3 months) suggests the stock is out of favor, which can persist. 3) Liquidity & Coverage Risk: With only one analyst providing estimates, price discovery is less efficient, which can lead to sharp, event-driven volatility as seen in February. 4) Sector Cyclicality Risk: The Global Housing segment is exposed to economic downturns, which could pressure margins and offset growth in the Lifestyle business.
The 12-month forecast for AIZ is range-bound with a neutral bias, based on three scenarios. The Base Case (55% probability) sees the stock trading between $225 and $245, assuming it meets the estimated EPS of $22.92. The Bull Case (30% probability) targets $246 to $265 on successful earnings execution and multiple expansion. The Bear Case (15% probability) warns of a drop to $183-$210 if earnings disappoint. The most likely scenario is the Base Case, as it aligns with the single analyst's average estimate and the stock's recent trading pattern. The key assumption is that the company delivers on its promised earnings recovery.
AIZ sends mixed valuation signals. On a forward-looking basis, it appears undervalued, trading at a forward P/E of 10.47x and a PEG ratio of 0.74, which is cheap for a profitable company. Its Price-to-Sales ratio of 0.95x is also low for the financial sector. However, based on trailing earnings (EPS of $0.07), the trailing P/E of 13.93x is high. The market is therefore pricing in a substantial earnings recovery. Compared to its own trading range and the market's growth expectations, AIZ is fairly valued to slightly undervalued, but this is entirely contingent on the earnings rebound materializing as forecasted.
AIZ is a conditional buy for value-oriented, patient investors. The forward P/E of 10.5x and PEG ratio of 0.74 suggest significant undervaluation if the forecasted EPS of $22.92 is achieved, offering substantial upside to the analyst-implied target. However, it is not a good buy for growth seekers or those sensitive to volatility, given its history of underperforming the market (-8.23% relative strength over 1 year) and reliance on a single analyst's forecast. The biggest downside risk is a failure of the earnings recovery, potentially leading to a -21% drop to the 52-week low of $183.
AIZ is more suitable for a long-term investment horizon (minimum 2-3 years) rather than short-term trading. Its low beta of 0.56 means it typically lacks the volatility for effective short-term trading, and the investment thesis is based on a multi-quarter earnings recovery story that needs time to unfold. The modest 1.39% dividend yield also contributes to a total-return approach over time. Short-term traders would likely be frustrated by its choppy, range-bound action and underperformance during market rallies. For long-term investors willing to look through cyclicality, AIZ offers a value proposition with defensive characteristics.